TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in female patients with severe aortic stenosis.

Dr Didier Tchétché (Clinique Pasteur, FR) joins us onsite at TCT Conference to discuss the pooled findings from the RHEIA (NCT04160130) and PARTNER 3 (NCT02675114) trials.

RHEIA and PARTNER 3 are prospective, controlled, multi-center trials, and in the pooled anlysis, 712 patients with severe aortic stenosis were randomized to receive either the SAPIEN 3 device (Edwards Lifesciences) or SAVR. In the RHEIA trial, all-female patients were enrolled and were followed-up at 30 days in-person, 6 months by telephone contact and visited in-person again at 1 year.  In the PARTNER 3 trial, male and female patients were enrolled and seen for follow-up visits at discharge, 30 days, 6 months and annually through 10 years. The primary outcome measures for both trials were mortality, stroke and re-hopitalisation. 

This analysis found that in women with symptomatic, severe aortic stenosis receiving TAVR with the SAPIEN 3 or SAPIEN 3 Ultra System, or surgical aortic valve replacement, the primary composite endpoint was superior for TAVR compared to surgery due to lower rehospitalization rates in this arm. Low rates of reintervention, endocarditis and thrombosis were observed in both treatment groups.

Interview Questions:
1.    What are the gender-related patient profile differences between patients receiving transcatheter heart valve replacement?
2.    Could you tell us about the trials' study designs and patient populations?
3.    What were the key findings?
4.    How should these findings impact clinical practice?
5.    What further study is needed in this area?

Recorded at TCT Conference in Washington, 2024.

Editors: Yazmin Sadik, Jordan Rance
Video Specialist: David Ben-Harosh, Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.